ANZCHOG Children’s Cancer Clinical Trials Repository | Australian & New Zealand Childrens Haematology/Oncology Group

The goal of the ANZCHOG Children’s Cancer Clinical Trials Repository (ACCCTR) is to provide a complete, up-to-date list of clinical trials conducted in children’s cancer centres in Australia and New Zealand.

This repository lists all clinical trials currently open, preparing to open, temporarily closed and recently closed to. The information provided should be used in conjunction with advice from health care professionals.

A large number of trials that are run at our children’s cancer centres in Australia and New Zealand are international trials. Further information regarding the clinical trials listed is available on national/ international clinical trial registries such as ANZCTR, clinicaltrials.gov and EU Clinical Trials Register.

Study Title	Protocol ID	Disease (Sub Disease)	Diagnosis Stage	Location	Links	Status	Trial Open Date	Sites	Study Type	Phase	Age Eligibility	ANZCTR	International registry ID's
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones	AALL1631	Leukaemia (ALL)	New diagnosis	NSW / QLD / WA	External Registry ≫	Open	19/04/2018	Treatment	Phase 3	1 year to 21 years at diagnosis		NCT03007147
A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)	AALL1731	Leukaemia (ALL)	New diagnosis	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	15/10/2019	Treatment	Phase 3	1 year to 31 Years		NCT03914625
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy	AALL1732	Leukaemia (ALL)	New Diagnosis	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	28/10/2019	Treatment	Phase 3	1 Year to 24 Years		NCT03959085
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	AAML1531	Leukaemia	New diagnosis	NSW / VIC / WA / NZ	External Registry ≫	Open	03/11/2015	Treatment	Phase 3	90 days to 4 years		NCT02521493
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP)	AAML18P1	Chronic Myeloid Leukaemia	On treatment	VIC / WA	External Registry ≫	Open	15/07/2019	Treatment	Phase 2	up to 25 years		NCT03817398
A phase I study of vinorelbine cyclophosphamide and Rapamycin for recurrent malignancies in children	ACCT007 (Rap-CV)	Malignancies	Relapsed/refractory	NSW / VIC / WA / SA / NZ	External Registry ≫	Open	09/08/2019	Treatment	Phase 1	up to 21 Years	ACTRN12613000423718
Application of innovative molecular profiling techniques to improve diagnosis of paediatric central nervous system tumours and develop an accredited Australasian molecular profiling service	ACCT009 (AIM BRAIN PROject)	Central Nervous System Tumours	New Diagnosis Relapse	NSW / QLD / VIC / WA / SA / NZ / TAS	External Registry ≫	Open	27/03/2018	Diagnosis	Not applicable	up to 21 years	ACTRN12618000006246
A Phase II Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years of Age	ACNS1221	Medulloblastoma	New diagnosis	NSW	External Registry ≫	Open	22/04/2014	Treatment	Phase 2	up to 47 Months		NCT02017964
A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients	ACNS1422	Medulloblastoma	New diagnosis	NSW / WA / SA	External Registry ≫	Open		Treatment	Phase 2	3 years to 22 years at the time of enrollment		NCT02724579
A Phase 2 Study of Veliparib (ABT-888 IND# 139199) and Local Irradiation Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations	ACNS1721	Anaplastic Astrocytoma Glioblastoma Malignant Glioma	New diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	31/10/2018	Treatment	Phase 2	3 Years to 25 Years		NCT03581292
Australian Cardio-Oncology Registry	ACOR	All tumour types	Newly diagnosed	NSW / QLD / VIC / WA / SA / TAS		Open	01/09/2018	Registry	Not applicable	up t 35 Years
A study to evaluate the safety and tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors	ACT001-AU-002	Advanced brain tumour Advanced solid tumour	Relapse/refractory	NSW / QLD	External Registry ≫	Open	18/09/2019	Treatment	Phase 1	1 Year to 21 Years	ACTRN12618001934235
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	AGCT1531	Germ Cell Tumour	New diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	08/05/2017	Treatment	Phase 3	Various depending on risk group & consult protocol		NCT03067181
Paediatric hepatic malignancy international therapeutic trial (PHITT)	AHEP1531	Hepatoblastoma Hepatocellular carcinoma	New diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	04/10/2018	Treatment	Phase 2/3	up to 30 Years		NCT03533582
Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	ALLELE (ATA129-EBV-302)	EBV post transplant	Refractory	VIC / WA	External Registry ≫	Open	29/12/2017	Treatment	Phase 3	no limits		NCT03394365
Key Adverse Events After Childhood Cancer	ALTE03N1	Childhood Malignant Neoplasm	Previously treated	QLD / WA / SA	External Registry ≫	Open	24/03/2004	Observational	Not applicable	up to 21 Years		NCT00082745
Neuropsychological and Social and Emotional and Behavioral Outcomes in Children with Cancer	ALTE07C1	All Tumour Types	New diagnosis Relapse/refractory	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	15/09/2008	Psycho-social	Not applicable	3 Years to 21 Years		NCT00772200
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy	ALTE11C2	Leukaemia Lymphoma	Previously treated	WA	External Registry ≫	Open	05/08/2013	Late Effects	Not applicable	no limits		NCT01790152
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study	ALTE15N2	Recurrent Neuroblastoma	Relapse/refractory	WA / NZ	External Registry ≫	Open	05/06/2017	Late Effects	Not applicable	5 Years to 50 Years		NCT03057626
Neuroblastoma Biology Studies	ANBL00B1	Solid tumours (Neuroblastoma)	New diagnosis	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	06/11/2000	Biology	Biology	5 Years to 50 Years		NCT03057626
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma	ANBL1232	Ganglioneuroblastoma Neuroblastoma	Relapse/refractory	NSW / QLD / WA / SA / NZ	External Registry ≫	Open	28/07/2014	Treatment	Phase 3	up to 18 months		NCT02176967
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma	ANBL1821	Solid tumours (Neuroblastoma)	Relapse/refractory	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	28/05/2019	Treatment	Phase 2	1 Year and older		NCT03794349
Pilot Study of Dinutuximab Sargramostim (GM-CSF) and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma	ANBL19P1	Neuroblastoma	New Diagnosis	WA	External Registry ≫	Open	30/11/2020	Treatment	Pilot	up to 30 Years		NCT04385277
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours	ANZUP 1302	Germ Cell Tumour	New diagnosis	QLD / NZ	External Registry ≫	Open	01/02/2014	Treatment	Phase 3	11 Years to 45 Years		NCT02582697
Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study	APEC14B1	All Tumour Types		NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	26/10/2015	Registry	Not applicable	up to 25 years		NCT02402244
Renal Tumors Classification Biology and Banking Study	AREN03B2	Renal tumours	Newly diagnosed	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	27/06/2007	Observational	Not applicable	up to 29 Years		NCT00898365
A Multicenter Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma	ARRAY-162-115	Solid tumours	New diagnosis Relapse/refractory	NSW / VIC	External Registry ≫	Open	13/08/2020	Treatment	Phase 1	12 Years to 17 Years		NCT03878719
A randomized Phase III study of vincristine& dactinomycin& cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TEM) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS)	ARST1431	Rhabdomyosarcoma	New diagnosis	NSW / QLD / WA / NZ	External Registry ≫	Open	09/12/2016	Treatment	Phase 3	under 40 years of age		NCT02567435
A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor Nirogacestat (PF-03084014) in Children and Adolescents With Progressive Surgically Unresectable Desmoid Tumors	ARST1921	Desmoid-Type Fibromatosis	New Diagnosis Relapse	WA	External Registry ≫	Open	21/09/2020	Treatment	Phase 2	12 Months to 18 Years		NCT04195399
Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in childhood leukaemia	ASSET	Leukaemia	Previously treated	NSW / VIC / WA / SA / NZ	External Registry ≫	Open	20/08/2015	Registry	Not applicable	up to 18 years
A randomised and open-label and active controlled and safety and extrapolated efficacy study in paediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event (Phase IV) Apixaban	B0661037	Venous Thromboembolism	New Diagnosis Relapse/Refractory	NSW	External Registry ≫	Open	02/08/2018	Treatment	Phase 4	3 Months to 17 Years		NCT02464969
Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study	Bu4Day-PK-2016	Haematopoietic Stem Cell Transplant	Newly diagnosed Relapsed/refractory	NSW / QLD / WA	External Registry ≫	Open	29/05/2017	Observational	Pilot	up to 18 years	ACTRN12617000227392
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children Adolescents and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)	CA045020 / NKTR-214	All tumour types	Relapsed/refractory	WA	External Registry ≫	Open	15/04/2021	Treatment	Phase 1/2	up to 30 years		NCT04730349
A Phase 1 Study of CD19 Specific Chimeric Antigen Receptor T-cell for Therapy of persistent and Relapsed B-cell leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study)	CARTELL	Leukaemia	Relapse/refractory	NSW	External Registry ≫	Open	19/11/2017	Treatment	Phase 1	no limits	ACTRN12617001579381
Developing genetically modified TCells for the treatment of paediatric solid tumours	CARTpaedST	Solid tumours	New diagnosis			Open	08/04/2018	Treatment	Phase 1	up to 18 years
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy	CCTL019A2205B		Previously treated	VIC	External Registry ≫	Open	02/11/2015	Observational	Not applicable	Child, Adult, Older Adult		NCT02445222
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia	CFZ2008 / 20140106	Acute Lymphoblastic Leukaemia (ALL)	Relapse/refractory	NSW / QLD / VIC	External Registry ≫	Open	10/09/2015	Treatment	Phase 1/2	1 Month to 21 Years		NCT02303821
A Phase I/II Open-label and Single-arm and Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation	CINC424F12201 / REACH4	Acute Graft Versus Host Disease	New Diagnosis Relapse/Refractory	NSW	External Registry ≫	Open	23/08/2018	Treatment	Phase 1/2	up to 17 years		NCT03491215
A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion	CONNECT1903	Brain and Spinal Tumours (High Grade Gliomas)	New diagnosis	WA	External Registry ≫	Open	08/04/2021	Treatment	Pilot	up to 21 years		NCT04655404
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma	DAY101-001 (FIREFLY)	Low-grade Glioma	Relapse/refractory	NSW / WA	External Registry ≫	Open	17/03/2021	Treatment	Phase 2	6 Months to 25 Years		NCT04775485
A Phase 1 Open-Label Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors Lymphoma and Malignant Brain Tumors	DCL-17-001	Various	Relapsed Refractory Recurrent	NSW	External Registry ≫	Open	30/04/2019	Treatment	Phase 1	2 Years to 25 Years		NCT03478462
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository	DIPG	Diffuse Intrinsic Pontine Glioma		WA	External Registry ≫	Open	30/06/2012	Registry	Not applicable	Child, Adult, Older Adult		NCT03101813
A Multicenter Open-label Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma	E7080-G000-230 (OLIE)	Solid tumours (Osteosarcoma)	Relapsed/ refractory	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	23/03/2020	Treatment	Phase 2	2 Years to 25 Years		NCT04154189
A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR)	ECREST	Solid tumours CNS tumours	Relapse/refractory	NSW / QLD	External Registry ≫	Open	08/02/2016	Treatment	Phase 1	2 Years to 21 Years		NCT02687386
A Phase 3 Open-label Multicenter Study of the Safety Efficacy and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A	EFC16295	Hemophilia A	Recurrent/ refractory	QLD	External Registry ≫	Open	19/02/2021	Treatment	Phase 3	up to 12 years		NCT04759131
A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	EZH102	Solid tumours	Relapse/ refractory	QLD	External Registry ≫	Open	27/05/2016	Treatment	Phase 1	6 months to 21 years		NCT02601937
Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue	HeadStart4	Medulloblastoma PNET	Newly diagnosed	NZ	External Registry ≫	Open	01/09/2015	Treatment	Phase 4	up to 10 Years		NCT02875314
Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma – developing DIPG cell cultures to test novel therapeutic strategies	HoTRODS	Diffuse Pontine Glioma Diffuse Midline Glioma High grade glioma	New Diagnosis Relapse	NSW / WA	External Registry ≫	Open	17/07/2012	Observational	Not applicable	no limits	ACTRN12612001183875
Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies	INFORM2 NivEnt	CNS Tumour Solid Tumour	Recurrent/ refractory	NSW / VIC / WA	External Registry ≫	Open	26/07/2019	Treatment	Phase 1/2	6 Years to 21 Years		NCT03838042
A clinical trial of donor-derived WT1 specific T cells for prevention of relapse in combination with multiple pathogen specific T cells for prevention of infection in patients undergoing allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia	INTACT-TAA	Leukaemia (AML)	Relapse/ refractory	NSW	External Registry ≫	Open	01/03/2017	Treatment	Phase 1	1 Year to 70 Years		NCT02895412
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma	J10-MC-JZHD	Solid tumours	Relapsed/ refractory	NSW / WA	External Registry ≫	Open	11/06/2020	Treatment	Phase 1	2 years to 21 years		NCT04106219
International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	LCH-IV	Langerhans Cell Histiocytosis	New diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	14/04/2014	Treatment	Phase 3	up to 18 years		NCT02205762
European Low and Intermediate Risk Neuroblastoma – A SIOPEN Study	LINES	Solid tumours(Neuroblastoma)	New diagnosis	NSW / VIC / WA	External Registry ≫	Open	31/05/2019	Treatment	Phase 3	90 days to 18 Years		NCT01728155
A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers	LOXO-EXT-17005	Solid tumours	Relapse/ refractory	NSW / VIC	External Registry ≫	Open	11/07/2018	Treatment	Phase 1/2	1 Month and older		NCT03215511
A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours	LOXO-RET-18036	Brain and Spinal Tumours	Relapse/ refractory	NSW / VIC	External Registry ≫	Open	01/07/2019	Treatment	Phase 1/2	6 months to 21 years		NCT03899792
A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors	LOXO-TRK-15003	Solid tumours	New diagnosis Relapse/ refractory	NSW / VIC	External Registry ≫	Open	11/09/2017	Treatment	Phase 1/2	up to 21 years		NCT02637687
A Phase I Study of the Safety and Pharmacokinetics of Venetoclax in Paediatric and Young Adult Patients with Relapsed or Refractory Malignancies	M13-833	Leukaemia (ALL/AML)	Relapse/ refractory	NSW / QLD / VIC / SA	External Registry ≫	Open	17/08/2017	Treatment	Phase 1	up to 25 years		NCT03236857
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma	MK-3475-051	Solid Tumour Lymphoma	Relapse/ refractory	NSW / QLD	External Registry ≫	Open	04/04/2016	Treatment	Phase 1/2	6 months to 17 years		NCT02332668
A Phase 2b open-label & single-arm study to evaluate pharmacokinetics& efficacy& safety and tolerability of letermovir in pediatric participants from birth to <18 years of age at risk of developing CMV infection and/or disease following allogeneic HSCT	MK-8228-030	Cytomegalovirus (CMV) Infection	New Diagnosis Relapse/Refractory	NSW / QLD / VIC	External Registry ≫	Open	08/08/2019	Treatment	Phase 2	up to 17 years		NCT03940586
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI)	NB SCI Registry	Neuroblastoma		NSW / QLD / VIC / WA / SA / TAS	External Registry ≫	Open	01/04/2015	Registry	Not applicable	up to 18 Years		NCT02559804
A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma	OZM-063 (LGG Avastin)	Brain and Spinal Tumours(Low Grade Gliomas)	New diagnosis Relapse/ refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	29/05/2018	Treatment	Phase 2	6 months to 18 years old		NCT02840409
Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers	OZM-075 (Hypermutant Cancer)	All Tumour Types	Relapse/ refractory	QLD / VIC / SA	External Registry ≫	Open	06/12/2019	Treatment	Pilot	12 months to 25 years		NCT02992964
Phase I/Ib trial of combined 5’azacitidine and carboplatin for recurrent/refractory pediatric brain and solid tumours	OZM-077 (COZMOS)	Brain and Spinal Tumours (Ependymoma)	Relapse/ refractory	NSW / QLD / VIC / WA / SA	External Registry ≫	Open	01/09/2019	Treatment	Phase 1	1 year to 18 years		NCT03206021
Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients	P3505	Haematological diseases	New Diagnosis Relapse/Refractory	QLD	External Registry ≫	Open	17/06/2020	Supportive Care	Phase 1	3 months to 18 years	ACTRN12620000141943
TCR a+ß+/CD19+ cell depleted haploidentical donor stem cell transplantation for paediatric patients	Pablo	Bone marrow transplant	New Diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	06/09/2018	Treatment	Phase 2	up to 18 years	ACTRN12617001174370
Phase 1/2 Dose Finding and Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)	PCYC-1146-IM	Chronic Graft Versus Host Disease	New Diagnosis Relapse/Refractory	NSW / VIC	External Registry ≫	Open	22/01/2019	Treatment	Phase 1/2	Part A – 1 to 12 years Part B – 1 to 22 years		NCT03790332
A Randomized Double-Blinded Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)	PNOC 0019	Brain and Spinal Tumours (High Grade Gliomas)	Relapsed/ refractory	NSW / WA	External Registry ≫	Open	01/03/2021	Treatment	Pilot	6 Months to 22 Years		NCT04323046
A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation	Ponatinib-1501 /AALL1922	Leukaemia (ALL)	Relapse/ refractory	VIC	External Registry ≫	Open	21/02/2021	Treatment	Phase 1/2	1 Year to 21 Years		NCT04501614
International Pleuropulmonary Blastoma Registry for PPB DICER1 and Associated Conditions	PPB DICER	Pleuropulmonary Blastoma		WA	External Registry ≫	Open	06/12/2015	Registry	Not applicable	Child, Adult, Older Adult		NCT03382158
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients	PREDICT	All tumour types	Newly diagnosed	NSW	External Registry ≫	Open	08/03/2021	Observational	Not applicable	up to 21 years		NCT04903782
PRecISion Medicine for Children with Cancer	PRISM	All Tumour Types	New Diagnosis Relapse/ Refractory	NSW / QLD / VIC / WA / SA	External Registry ≫	Open	05/09/2017	Biology	Biology	up to 21 years		NCT03336931
Ph3 Randomized Double-Blind Placebo-Controlled Parallel-Group Study With Open Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)	PRN1008-018	Immune Thrombocytopenia	Recurrent/ refractory	QLD	External Registry ≫	Open	14/12/2020	Treatment	Phase 3	12 Years and older		NCT04562766
A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation	R3ACT Fungal	Invasive Fungal Disease	Newly diagnosed Relapsed/Refractory	NSW	External Registry ≫	Open	19/08/2019	Treatment	Phase 1	1 Years to 80 Years	ACTRN12618001540202
A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma	ReRAD	Brain and Spinal Tumours	Relapsed/ refractory	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	15/04/2017	Treatment	Phase 2	up to 17 years		NCT03126266
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	RG_13-277 (rEECur)	Solid tumours (Ewings sarcoma)	Relapse/ refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	03/04/2018	Treatment	Phase 2/3	4 years to 50 years	ACTRN12618001825246
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy	RG_14-088 (MyeChild-01)	Leukaemia (AML)	New diagnosis	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	04/07/2018	Treatment	Phase 3	up to 18 years		NCT02724163
A Phase II study evaluating the activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory Cancers of childhood	RG_16-040 (PARC)	All Tumour Types (Other)	Relapse/ refractory	NSW / QLD / VIC / WA / SA	External Registry ≫	Open	29/11/2019	Treatment	Phase 1/2	1 year to 25 years		NCT03455140
An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma	RG_17-427 (FAR-RMS)	Rhabdomyosarcoma	Relapsed/ refractory	VIC / NZ	External Registry ≫	Open	17/09/2020	Treatment	Phase 1	no limits		NCT04625907
Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors	SJ ELiOT	Brain and Spinal Tumours (Medulloblastoma/ PNET)	Relapse/ refractory	NSW / QLD / VIC / WA	External Registry ≫	Open	02/10/2019	Treatment	Phase 1	1 year to 25 years		NCT04023669
A Clinical and Molecular Risk-Directed Therapy For Newly Diagnosed Medulloblastoma	SJMB12	Brain and Spinal Tumours (Medulloblastoma/PNET)	New diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	12/03/2014	Treatment	Phase 3	3 Years to 39 Years		NCT01878617
International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (A randomized Phase III study conducted by the AIEOP-BFM study group)	Study10	Lymphoblastic leukaemia	Newly diagnosed	NSW	External Registry ≫	Open	15/07/2018	Treatment	Phase 3	up to 17 Years		NCT03643276
A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda)	T2017-002	Leukaemia (ALL)	Relapsed/ refractory	NSW	External Registry ≫	Open	12/02/2019	Treatment	Phase 1/2	1 Year to 21 Years		NCT03817320
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	TAPISTRY	All tumour types	Relapsed/ refractory	NSW	External Registry ≫	Open	18/01/2021	Treatment	Phase 2	no limits		NCT04589845
A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas	TiNT	Solid tumours (Other Solid Tumour)	Relapsed/ refractory	NSW / QLD / VIC / WA / NZ / TAS	External Registry ≫	Open	01/03/2021	Treatment	Phase 2	3 Months to 25 Years	ACTRN12620001229965
A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations	TPX-0005-07	Solid tumours	Relapsed/ refractory	NSW / QLD / WA	External Registry ≫	Open	20/03/2020	Treatment	Phase 1/2	up to 25 years		NCT04094610

Study Title

Protocol ID

Disease (Sub Disease)

Diagnosis Stage

Location

Links

Status

Trial Open Date

Trial Close Date

Sites

Study Type

Phase

Age Eligibility

ANZCTR

International registry ID's

International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

AALL1631

Leukaemia (ALL)

New diagnosis

NSW / QLD / WA